E-type prostanoid receptor 4 (EP4) in disease and therapy

[1]  E. Baik,et al.  Prostaglandin E2‐induced intercellular adhesion molecule‐1 expression is mediated by cAMP/Epac signalling modules in bEnd.3 brain endothelial cells , 2013, British journal of pharmacology.

[2]  M. Kondo,et al.  Differential regulation of airway smooth muscle cell migration by E-prostanoid receptor subtypes. , 2013, American journal of respiratory cell and molecular biology.

[3]  V. Kónya,et al.  Endothelial E-type prostanoid 4 receptors promote barrier function and inhibit neutrophil trafficking. , 2013, The Journal of allergy and clinical immunology.

[4]  Pierre Validire,et al.  The cyclooxygenase-2-prostaglandin E2 pathway maintains senescence of chronic obstructive pulmonary disease fibroblasts. , 2013, American journal of respiratory and critical care medicine.

[5]  Raj Gaurav Rohatgi,et al.  Prostaglandin E(2) mediates proliferation and chloride secretion in ADPKD cystic renal epithelia. , 2012, American journal of physiology. Renal physiology.

[6]  S. Narumiya,et al.  The PGE(2)-EP4 receptor is necessary for stimulation of the renin-angiotensin-aldosterone system in response to low dietary salt intake in vivo. , 2012, American journal of physiology. Renal physiology.

[7]  Jiandang Shi,et al.  Prostaglandin E2 stimulates S100A8 expression by activating protein kinase A and CCAAT/enhancer-binding-protein-beta in prostate cancer cells. , 2012, The international journal of biochemistry & cell biology.

[8]  M. Peinado,et al.  Epigenetic deregulation of the COX pathway in cancer. , 2012, Progress in lipid research.

[9]  R. Jakab,et al.  Lubiprostone Targets Prostanoid Signaling and Promotes Ion Transporter Trafficking, Mucus Exocytosis, and Contractility , 2012, Digestive Diseases and Sciences.

[10]  I. Mlinarič-Raščan,et al.  EP4 receptor signalling in immature B cells involves cAMP and NF‐κB dependent pathways , 2012, The Journal of pharmacy and pharmacology.

[11]  S. Narumiya,et al.  Temporal expression of the PGE2 synthetic system in the kidney is associated with the time frame of renal developmental vulnerability to cyclooxygenase-2 inhibition. , 2012, American journal of physiology. Renal physiology.

[12]  S. Narumiya,et al.  The intrinsic prostaglandin E2-EP4 system of the renal tubular epithelium limits the development of tubulointerstitial fibrosis in mice. , 2012, Kidney international.

[13]  C. Funk,et al.  Prostaglandin receptor EP4 in abdominal aortic aneurysms. , 2012, The American journal of pathology.

[14]  M. Toda,et al.  Synthesis and evaluation of γ-lactam analogs of PGE₂ as EP4 and EP2/EP4 agonists. , 2012, Bioorganic & medicinal chemistry.

[15]  T. Maruyama,et al.  Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model , 2012, Laboratory Investigation.

[16]  S. Okumura,et al.  Inhibition of EP4 Signaling Attenuates Aortic Aneurysm Formation , 2012, PloS one.

[17]  L. Holdt,et al.  Sepsis-associated changes of the arachidonic acid metabolism and their diagnostic potential in septic patients* , 2012, Critical care medicine.

[18]  T. Nishihara,et al.  Oral administration of prostaglandin E(2)-specific receptor 4 antagonist inhibits lipopolysaccharide-induced osteoclastogenesis in rat periodontal tissue. , 2012, Journal of periodontology.

[19]  R. Young,et al.  Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis. , 2012, Bioorganic & medicinal chemistry.

[20]  S. Narumiya,et al.  Role of PGE-type receptor 4 in auditory function and noise-induced hearing loss in mice , 2012, Neuropharmacology.

[21]  S. Narumiya,et al.  Improvement of cognitive function in Alzheimer’s disease model mice by genetic and pharmacological inhibition of the EP4 receptor , 2012, Journal of neurochemistry.

[22]  Andrew J. Johnson,et al.  The role of prostanoid receptors in mediating the effects of PGE3 on human platelet function , 2012, Thrombosis and Haemostasis.

[23]  P. Libby,et al.  Anti-inflammation Therapy by Activation of Prostaglandin EP4 Receptor in Cardiovascular and Other Inflammatory Diseases , 2012, Journal of cardiovascular pharmacology.

[24]  D. Longrois,et al.  PGE(2) receptor (EP(4)) agonists: potent dilators of human bronchi and future asthma therapy? , 2012, Pulmonary pharmacology & therapeutics.

[25]  V. Gogvadze,et al.  Autocrine Prostaglandin E2 Signaling Promotes Tumor Cell Survival and Proliferation in Childhood Neuroblastoma , 2012, PloS one.

[26]  M. Kondo,et al.  Prostaglandin E2 enhances interleukin-8 production via EP4 receptor in human pulmonary microvascular endothelial cells. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[27]  P. Kalinski.  Regulation of Immune Responses by Prostaglandin E2 , 2012, The Journal of Immunology.

[28]  K. Odunsi,et al.  PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. , 2011, Cancer research.

[29]  R. Edwards,et al.  Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. , 2011, Blood.

[30]  Y. Daaka,et al.  PGE2 promotes angiogenesis through EP4 and PKA Cγ pathway. , 2011, Blood.

[31]  M. Merchant,et al.  Signaling via the prostaglandin E₂ receptor EP4 exerts neuronal and vascular protection in a mouse model of cerebral ischemia. , 2011, The Journal of clinical investigation.

[32]  J. Rundhaug,et al.  The role of the EP receptors for prostaglandin E2 in skin and skin cancer , 2011, Cancer and Metastasis Reviews.

[33]  D. Ganea,et al.  Prostaglandin E2 Induces Matrix Metalloproteinase 9 Expression in Dendritic Cells through Two Independent Signaling Pathways Leading to Activator Protein 1 (AP-1) Activation , 2011, The Journal of Biological Chemistry.

[34]  Hiroshi Ito,et al.  Endogenous prostaglandin E2 inhibits aberrant overgrowth of rheumatoid synovial tissue and the development of osteoclast activity through EP4 receptor. , 2011, Arthritis and rheumatism.

[35]  M. Chancellor,et al.  Mechanisms and urodynamic effects of a potent and selective EP4 receptor antagonist, MF191, on cyclophosphamide and prostaglandin E2‐induced bladder overactivity in rats , 2011, BJU international.

[36]  Y. Daaka,et al.  Prostaglandin E2 Regulates Renal Cell Carcinoma Invasion through the EP4 Receptor-Rap GTPase Signal Transduction Pathway* , 2011, The Journal of Biological Chemistry.

[37]  B. Koller,et al.  A major role for the EP4 receptor in regulation of renin. , 2011, American journal of physiology. Renal physiology.

[38]  Lance E. Lanyon,et al.  Sost down-regulation by mechanical strain in human osteoblastic cells involves PGE2 signaling via EP4 , 2011, FEBS letters.

[39]  I. Mlinarič-Raščan,et al.  Prostaglandin EP4 receptor enhances BCR-induced apoptosis of immature B cells. , 2011, Prostaglandins & other lipid mediators.

[40]  A. Olschewski,et al.  Interaction of eosinophils with endothelial cells is modulated by prostaglandin EP4 receptors , 2011, European journal of immunology.

[41]  Y. Sugimoto,et al.  Prostaglandin E2-EP4 signaling suppresses adipocyte differentiation in mouse embryonic fibroblasts via an autocrine mechanism[S] , 2011, Journal of Lipid Research.

[42]  J. Sastre,et al.  PGE2 decreases muscle cell proliferation in patients with non-asthmatic eosinophilic bronchitis , 2011 .

[43]  S. Narumiya,et al.  Central PGE2 exhibits anxiolytic‐like activity via EP1 and EP4 receptors in a manner dependent on serotonin 5‐HT1A, dopamine D1 and GABAA receptors , 2011, FEBS letters.

[44]  R. Fenton,et al.  Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus , 2011, Proceedings of the National Academy of Sciences.

[45]  Xinrong Ma,et al.  Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4 , 2011, Cancer Immunology, Immunotherapy.

[46]  M. Belvisi,et al.  EP4 receptor as a new target for bronchodilator therapy , 2011, Thorax.

[47]  H. Jabbour,et al.  Hypoxia and Prostaglandin E Receptor 4 Signalling Pathways Synergise to Promote Endometrial Adenocarcinoma Cell Proliferation and Tumour Growth , 2011, PloS one.

[48]  K. Alitalo,et al.  Roles of Prostaglandin E2–EP3/EP4 Receptor Signaling in the Enhancement of Lymphangiogenesis During Fibroblast Growth Factor-2–Induced Granulation Formation , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[49]  V. Cerundolo,et al.  Prostaglandin E2 suppresses the differentiation of retinoic acid–producing dendritic cells in mice and humans , 2011, The Journal of experimental medicine.

[50]  S. Narumiya,et al.  Prostaglandin E2–prostoglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression , 2011, Proceedings of the National Academy of Sciences.

[51]  E. Fröhlich,et al.  EP4 receptor stimulation down-regulates human eosinophil function , 2011, Cellular and Molecular Life Sciences.

[52]  M. Isobe,et al.  The Anti-Inflammatory Mechanism of Prostaglandin E2 Receptor 4 Activation in Rat Experimental Autoimmune Myocarditis , 2011, Journal of cardiovascular pharmacology.

[53]  P. Libby,et al.  Deletion of EP4 on Bone Marrow–Derived Cells Enhances Inflammation and Angiotensin II–Induced Abdominal Aortic Aneurysm Formation , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[54]  T. Ishikawa,et al.  Prostaglandin E₂ signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. , 2011, Gastroenterology.

[55]  E. Cowley,et al.  Activation of the EP₄ prostanoid receptor induces prostaglandin E₂ and pro-inflammatory cytokine production in human airway epithelial cells. , 2011, Pulmonary pharmacology & therapeutics.

[56]  A. Starzinski-Powitz,et al.  Selective inhibition of prostaglandin E2 receptors EP2 and EP4 inhibits invasion of human immortalized endometriotic epithelial and stromal cells through suppression of metalloproteinases , 2011, Molecular and Cellular Endocrinology.

[57]  A. Cuthbert.  Lubiprostone targets prostanoid EP4 receptors in ovine airways , 2011, British journal of pharmacology.

[58]  V. Kónya,et al.  The Prostaglandin E2 Receptor EP4 Is Expressed by Human Platelets and Potently Inhibits Platelet Aggregation and Thrombus Formation* , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[59]  Jidong Zhang,et al.  Tumor-secreted PGE2 Inhibits CCL5 Production in Activated Macrophages through cAMP/PKA Signaling Pathway* , 2010, The Journal of Biological Chemistry.

[60]  C. Vandevoort,et al.  Mammalian oocytes are targets for prostaglandin E2 (PGE2) action , 2010, Reproductive biology and endocrinology : RB&E.

[61]  B. Vanderhyden,et al.  A maladaptive role for EP4 receptors in podocytes. , 2010, Journal of the American Society of Nephrology : JASN.

[62]  C. Jean,et al.  PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. , 2010, Biochemical pharmacology.

[63]  G. Rogler,et al.  Prostaglandin E2 inhibits migration of colonic lamina propria fibroblasts , 2010, Inflammatory bowel diseases.

[64]  K. Sugiura,et al.  Involvement of endogenous prostaglandin E2 in tubular epithelial regeneration through inhibition of apoptosis and epithelial-mesenchymal transition in cisplatin-induced rat renal lesions. , 2010, Histology and histopathology.

[65]  A. Yoshida,et al.  Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation , 2010, Thrombosis and Haemostasis.

[66]  Andrew J. Johnson,et al.  The role of prostanoid receptors in mediating the effects of PGE2 on human platelet function , 2010, Platelets.

[67]  O. Boutaud,et al.  PGE2 decreases reactivity of human platelets by activating EP2 and EP4. , 2010, Thrombosis research.

[68]  Y. Shih,et al.  EP4 upregulation of Ras signaling and feedback regulation of Ras in human colon tissues and cancer cells , 2010, Archives of Toxicology.

[69]  T. Montine,et al.  The Prostaglandin E2 E-Prostanoid 4 Receptor Exerts Anti-Inflammatory Effects in Brain Innate Immunity , 2010, The Journal of Immunology.

[70]  Steve Rowland,et al.  Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain. , 2010, Bioorganic & medicinal chemistry letters.

[71]  S. Narumiya,et al.  Effect of EP4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: a randomized phase II, placebo-controlled trial. , 2010, Inflammatory bowel diseases.

[72]  T. Sumida,et al.  A novel antagonist of the prostaglandin E2 EP4 receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models , 2010, British journal of pharmacology.

[73]  C. Geisler,et al.  COX-2-dependent PGE2 acts as a growth factor in mycosis fungoides (MF) , 2010, Leukemia.

[74]  J. Ito,et al.  Role of prostaglandin E receptor subtypes EP2 and EP4 in autocrine and paracrine functions of vascular endothelial growth factor in the inner ear , 2010, BMC Neuroscience.

[75]  Yasushi Okuno,et al.  Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. , 2010, Cancer research.

[76]  S. Narumiya,et al.  Prostaglandin E2, an immunoactivator. , 2010, Journal of pharmacological sciences.

[77]  Á. Lanas,et al.  Prostaglandin EP2 receptor expression is increased in Barrett’s oesophagus and oesophageal adenocarcinoma , 2010, Alimentary pharmacology & therapeutics.

[78]  G. Herrero-Beaumont,et al.  Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis. , 2010, Arthritis and rheumatism.

[79]  K. Yudoh,et al.  Prostaglandin E2 regulates the expression of connective tissue growth factor (CTGF/CCN2) in human osteoarthritic chondrocytes via the EP4 receptor , 2010, BMC Research Notes.

[80]  T. Grosser,et al.  Emotion recollected in tranquility: lessons learned from the COX-2 saga. , 2010, Annual review of medicine.

[81]  K. Debatin,et al.  Prostaglandin E2 Inhibits IFN-α Secretion and Th1 Costimulation by Human Plasmacytoid Dendritic Cells via E-Prostanoid 2 and E-Prostanoid 4 Receptor Engagement , 2009, The Journal of Immunology.

[82]  Takashi Nakamura,et al.  PGE2 inhibits MMP expression by suppressing MKK4–JNK MAP kinase–c‐JUN pathway via EP4 in human articular chondrocytes , 2009, Journal of cellular biochemistry.

[83]  E. White,et al.  Prostaglandin E2 induces fibroblast apoptosis by modulating multiple survival pathways , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[84]  B. Jessen,et al.  Corneal Neovascularization and Ocular Irritancy Responses in Dogs Following Topical Ocular Administration of an EP4-Prostaglandin E2 Agonist , 2009, Toxicologic pathology.

[85]  S. Baek,et al.  The Cyclooxygenase Inhibitor Sulindac Sulfide Inhibits EP4 Expression and Suppresses the Growth of Glioblastoma Cells , 2009, Cancer Prevention Research.

[86]  A. Heinemann,et al.  Prostaglandin E2 acts via the EP4 receptor to inhibit platelet aggregation , 2009, BMC Pharmacology.

[87]  N. Misso,et al.  Prostaglandin E2 and cysteinyl leukotriene concentrations in sputum: association with asthma severity and eosinophilic inflammation , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[88]  F. Jamali,et al.  Renal adverse effects of nonsteroidal anti-inflammatory drugs , 2009, Expert opinion on drug safety.

[89]  P. Wells,et al.  Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models. , 2009, Experimental eye research.

[90]  J. Wess,et al.  A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. , 2009, The Journal of clinical investigation.

[91]  N. Heveker,et al.  Functional Selectivity of Natural and Synthetic Prostaglandin EP4 Receptor Ligands , 2009, Journal of Pharmacology and Experimental Therapeutics.

[92]  S. Ostrand-Rosenberg,et al.  Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function , 2009, Breast Cancer Research and Treatment.

[93]  R. Guldberg,et al.  Rescue of impaired fracture healing in COX-2-/- mice via activation of prostaglandin E2 receptor subtype 4. , 2009, The American journal of pathology.

[94]  S. Pasvanis,et al.  CCR7-specific migration to CCL19 and CCL21 is induced by PGE(2) stimulation in human monocytes: Involvement of EP(2)/EP(4) receptors activation. , 2009, Molecular immunology.

[95]  V. Speights,et al.  Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkappaB, and beta-catenin pathways and activation of intrinsic apoptotic mechanisms. , 2009, Molecular endocrinology.

[96]  M. Isobe,et al.  The Mechanism of Anti-Inflammatory Effects of Prostaglandin E2 Receptor 4 Activation in Murine Cardiac Transplantation , 2009, Transplantation.

[97]  S. Narumiya,et al.  Prostaglandin E2–EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion , 2009, Nature Medicine.

[98]  E. Shim,et al.  Forskolin increases angiogenesis through the coordinated cross-talk of PKA-dependent VEGF expression and Epac-mediated PI3K/Akt/eNOS signaling. , 2009, Cellular signalling.

[99]  N. Joo,et al.  Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[100]  F. Sallusto,et al.  Prostaglandin E2 enhances Th17 responses via modulation of IL‐17 and IFN‐γ production by memory CD4+ T cells , 2009, European journal of immunology.

[101]  Randall Harris,et al.  Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung , 2009, Inflammopharmacology.

[102]  T. Mcclanahan,et al.  Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling , 2009, The Journal of experimental medicine.

[103]  M. Giembycz,et al.  Prostaglandin E2 couples through EP4 prostanoid receptors to induce IL‐8 production in human colonic epithelial cell lines , 2009, British journal of pharmacology.

[104]  C. Routledge,et al.  BGC20‐1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache , 2009, British journal of pharmacology.

[105]  X. Gidrol,et al.  Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4 , 2008, The Journal of experimental medicine.

[106]  J. Oates,et al.  Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis. , 2008, Cell metabolism.

[107]  K. Gomi,et al.  PGE(2) induces COX-2 expression in podocytes via the EP(4) receptor through a PKA-independent mechanism. , 2008, Cellular signalling.

[108]  S. Coughlin,et al.  Anatomical Profiling of G Protein-Coupled Receptor Expression , 2008, Cell.

[109]  Y. Ishikawa,et al.  Prostaglandin E2-activated Epac Promotes Neointimal Formation of the Rat Ductus Arteriosus by a Process Distinct from That of cAMP-dependent Protein Kinase A* , 2008, Journal of Biological Chemistry.

[110]  S. Abramson,et al.  Prostaglandin E2 Exerts Catabolic Effects in Osteoarthritis Cartilage: Evidence for Signaling via the EP4 Receptor1 , 2008, The Journal of Immunology.

[111]  Y. Urade,et al.  Lipopolysaccharide Induces Macrophage Migration via Prostaglandin D2 and Prostaglandin E2 , 2008, Journal of Pharmacology and Experimental Therapeutics.

[112]  L. Louedec,et al.  Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype , 2008, British journal of pharmacology.

[113]  D. Glavač,et al.  Cyclooxygenase in normal human tissues – is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? , 2008, Journal of cellular and molecular medicine.

[114]  Koji Takeuchi,et al.  Gastric mucosal defense and cytoprotection: bench to bedside. , 2008, Gastroenterology.

[115]  Y. Murata,et al.  Effects of the selective EP4 antagonist, CJ‐023,423 on chronic inflammation and bone destruction in rat adjuvant‐induced arthritis , 2008, The Journal of pharmacy and pharmacology.

[116]  R. Borman,et al.  Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon , 2008, British journal of pharmacology.

[117]  H. Reber,et al.  Opposing Effects of n-6 and n-3 Polyunsaturated Fatty Acids on Pancreatic Cancer Growth , 2008, Pancreas.

[118]  P. Clark,et al.  MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a Selective E Prostanoid Receptor 4 Antagonist, Relieves Joint Inflammation and Pain in Rodent Models of Rheumatoid and Osteoarthritis , 2008, Journal of Pharmacology and Experimental Therapeutics.

[119]  M. Pan,et al.  Cyclooxygenase-2 Up-regulates CCR7 via EP2/EP4 Receptor Signaling Pathways to Enhance Lymphatic Invasion of Breast Cancer Cells* , 2008, Journal of Biological Chemistry.

[120]  P. Libby,et al.  Prostaglandin E Receptor Type 4-associated Protein Interacts Directly with NF-κB1 and Attenuates Macrophage Activation* , 2008, Journal of Biological Chemistry.

[121]  C. Hao,et al.  Physiological regulation of prostaglandins in the kidney. , 2008, Annual review of physiology.

[122]  Andrew P. Joy,et al.  8-iso-PGE2 stimulates anion efflux from airway epithelial cells via the EP4 prostanoid receptor. , 2008, American journal of respiratory cell and molecular biology.

[123]  S. Akira,et al.  Induction of prostaglandin E2 synthesis and microsomal prostaglandin E synthase-1 expression in murine microglia by glioma-derived soluble factors. Laboratory investigation. , 2008, Journal of neurosurgery.

[124]  Kazunari Nakao,et al.  In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP(4) receptor antagonist. , 2008, Life sciences.

[125]  Bagna Bao,et al.  Synthesis and evaluation of a γ-lactam as a highly selective EP2 and EP4 receptor agonist , 2008 .

[126]  Andrew J. Johnson,et al.  DG-041 inhibits the EP3 prostanoid receptor—A new target for inhibition of platelet function in atherothrombotic disease , 2008, Platelets.

[127]  G. FitzGerald,et al.  COX-2 inhibitors and cardiovascular risk. , 2007, Journal of cardiovascular pharmacology.

[128]  N. Kanayama,et al.  Prostaglandin E2 receptor EP4‐selective antagonist inhibits lipopolysaccharide‐induced cervical ripening in rabbits , 2007, Acta obstetricia et gynecologica Scandinavica.

[129]  T. Moilanen,et al.  Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process. , 2007, Basic & clinical pharmacology & toxicology.

[130]  K. Takeuchi,et al.  Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[131]  X. Norel.  Prostanoid Receptors in the Human Vascular Wall , 2007, TheScientificWorldJournal.

[132]  S. Narumiya,et al.  Prostaglandin E2 Induces Vascular Relaxation by E-Prostanoid 4 Receptor-Mediated Activation of Endothelial Nitric Oxide Synthase , 2007, Hypertension.

[133]  Elena Alekseeva,et al.  Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation. , 2007, Experimental cell research.

[134]  R. Tuma,et al.  The Proinflammatory Effect of Prostaglandin E2 in Experimental Inflammatory Bowel Disease Is Mediated through the IL-23→IL-17 Axis1 , 2007, The Journal of Immunology.

[135]  A. Pozzi,et al.  Prostaglandin E2-EP4 Receptor Promotes Endothelial Cell Migration via ERK Activation and Angiogenesis in Vivo* , 2007, Journal of Biological Chemistry.

[136]  K. Takeuchi,et al.  Involvement of prostaglandin E receptor EP3 subtype in duodenal bicarbonate secretion in rats. , 2007, Life sciences.

[137]  M. Hull,et al.  Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells , 2007, Oncogene.

[138]  I. Dougall,et al.  Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-α release from human alveolar macrophages , 2007, European Respiratory Journal.

[139]  J. Vonesch,et al.  Vascular wall–produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors , 2007, The Journal of experimental medicine.

[140]  S. Nakashima,et al.  Prostaglandin E2 downregulates TNF‐α‐induced production of matrix metalloproteinase‐1 in HCS‐2/8 chondrocytes by inhibiting Raf‐1/MEK/ERK cascade through EP4 prostanoid receptor activation , 2007, Journal of cellular biochemistry.

[141]  T. Maruyama,et al.  Prostaglandin E receptor EP4 antagonist suppresses osteolysis due to bone metastasis of mouse malignant melanoma cells , 2007, FEBS letters.

[142]  A. Blikslager,et al.  Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[143]  L. Wheeler,et al.  The Prevention of Colitis by E Prostanoid Receptor 4 Agonist through Enhancement of Epithelium Survival and Regeneration , 2007, Journal of Pharmacology and Experimental Therapeutics.

[144]  Y. Ishikawa,et al.  Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. , 2006, The Journal of clinical investigation.

[145]  J. Hewett,et al.  Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system. , 2006, Pharmacology & therapeutics.

[146]  D. Srivastava,et al.  The paradoxical patent ductus arteriosus. , 2006, The Journal of clinical investigation.

[147]  D. Carbone,et al.  Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. , 2006, Cancer research.

[148]  M. Yoshikawa,et al.  Activation of prostaglandin E receptor EP4 subtype suppresses food intake in mice. , 2006, Prostaglandins & other lipid mediators.

[149]  S. Vukicevic,et al.  Role of EP2 and EP4 receptor-selective agonists of prostaglandin E(2) in acute and chronic kidney failure. , 2006, Kidney international.

[150]  O. Ogunwobi,et al.  Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. , 2006, Endocrinology.

[151]  R. Levy,et al.  Induction of Fc gammaRIIA expression in myeloid PLB cells during differentiation depends on cytosolic phospholipase A2 activity and is regulated via activation of CREB by PGE2. , 2006, Blood.

[152]  M. Nishibori,et al.  E prostanoid 2 (EP2)/EP4‐mediated suppression of antigen‐specific human T‐cell responses by prostaglandin E2 , 2006, Immunology.

[153]  A. Tenenhouse,et al.  The effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian Multicentre Osteoporosis Study , 2006, Osteoporosis International.

[154]  J. Redondo,et al.  Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases. , 2006, Cardiovascular research.

[155]  T. Takano,et al.  Prostaglandin E2 promotes cell survival of glomerular epithelial cells via the EP4 receptor. , 2006, American journal of physiology. Renal physiology.

[156]  J. Christman,et al.  Involvement of cyclooxygenase-2 and prostaglandins in the molecular pathogenesis of inflammatory lung diseases. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[157]  G. Caron,et al.  Histamine and prostaglandin E2 up‐regulate the production of Th2‐attracting chemokines (CCL17 and CCL22) and down‐regulate IFN‐γ‐induced CXCL10 production by immature human dendritic cells , 2006, Immunology.

[158]  A. C. Williams,et al.  Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. , 2006, Cancer research.

[159]  Xinrong Ma,et al.  Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. , 2006, Cancer research.

[160]  P. Libby,et al.  A Novel Prostaglandin E Receptor 4–Associated Protein Participates in Antiinflammatory Signaling , 2006, Circulation research.

[161]  Qiong Shi,et al.  Role of β-arrestin 1 in the metastatic progression of colorectal cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[162]  J. Regan,et al.  EP4 Prostanoid Receptor Coupling to a Pertussis Toxin-Sensitive Inhibitory G Protein , 2006, Molecular Pharmacology.

[163]  K. Ha,et al.  Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells , 2005, Experimental & Molecular Medicine.

[164]  S. Narumiya,et al.  Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3 , 2005, Nature Immunology.

[165]  Garret A FitzGerald,et al.  Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. , 2005, The Journal of clinical investigation.

[166]  N. Udagawa,et al.  Prostaglandin E2 strongly inhibits human osteoclast formation. , 2005, Endocrinology.

[167]  Makoto Murakami,et al.  Prostaglandin E synthase, a terminal enzyme for prostaglandin E2 biosynthesis. , 2005, Journal of biochemistry and molecular biology.

[168]  R. Nüsing,et al.  Prostaglandin E2 EP2 and EP4 receptor activation mediates cAMP-dependent hyperpolarization and exocytosis of renin in juxtaglomerular cells. , 2005, American journal of physiology. Renal physiology.

[169]  M. Sho,et al.  Significance and therapeutic potential of prostaglandin E2 receptor in hepatic ischemia/reperfusion injury in mice , 2005, Hepatology.

[170]  S. Narumiya,et al.  Dominant role of prostaglandin E2 EP4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome. , 2005, Journal of the American Society of Nephrology : JASN.

[171]  Li Zhu,et al.  PGE2 confers survivin‐dependent apoptosis resistance in human monocyte‐derived dendritic cells , 2005, Journal of leukocyte biology.

[172]  M. Huang,et al.  Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. , 2005, Cancer research.

[173]  A. Tanaka,et al.  Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. , 2005, Journal of medicinal chemistry.

[174]  K. Yamagata,et al.  Augmentation of allergic inflammation in the airways of cyclooxygenase‐2‐deficient mice , 2005, Respirology.

[175]  N. Kanayama,et al.  The selective prostaglandin EP4 agonist, APS-999 Na, induces follicular growth and maturation in the rat ovary. , 2005, European journal of endocrinology.

[176]  F. Spinella,et al.  Endothelin-1-induced Prostaglandin E2-EP2, EP4 Signaling Regulates Vascular Endothelial Growth Factor Production and Ovarian Carcinoma Cell Invasion* , 2004, Journal of Biological Chemistry.

[177]  U. Moens,et al.  What turns CREB on? , 2004, Cellular signalling.

[178]  Melissa M. Haskell,et al.  ClC-2 chloride secretion mediates prostaglandin-induced recovery of barrier function in ischemia-injured porcine ileum. , 2004, Gastroenterology.

[179]  S. Narumiya,et al.  Stimulation of renin release by prostaglandin E2 is mediated by EP2 and EP4 receptors in mouse kidneys. , 2004, American journal of physiology. Renal physiology.

[180]  J. Morrow,et al.  Colon Carcinoma Cell Growth Is Associated with Prostaglandin E2/EP4 Receptor-evoked ERK Activation* , 2004, Journal of Biological Chemistry.

[181]  T. Yoshino,et al.  E-Prostanoid (EP)2/EP4 Receptor-Dependent Maturation of Human Monocyte-Derived Dendritic Cells and Induction of Helper T2 Polarization , 2004, Journal of Pharmacology and Experimental Therapeutics.

[182]  S. Narumiya,et al.  Prostaglandin E2 Protects the Heart From Ischemia-Reperfusion Injury via Its Receptor Subtype EP4 , 2004, Circulation.

[183]  J. Regan.  EP2 and EP4 prostanoid receptor signaling. , 2003, Life sciences.

[184]  D. Ganea,et al.  Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells , 2003, Journal of leukocyte biology.

[185]  Guoxiong Xu,et al.  Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. , 2003, Experimental cell research.

[186]  H. Young,et al.  Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. , 2003, Blood.

[187]  J. Bos.  Epac: a new cAMP target and new avenues in cAMP research , 2003, Nature Reviews Molecular Cell Biology.

[188]  B. Wiesner,et al.  The prostaglandin E2 analogue sulprostone antagonizes vasopressin-induced antidiuresis through activation of Rho , 2003, Journal of Cell Science.

[189]  S. Narumiya,et al.  Prostaglandin E2–EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells , 2003, Nature Medicine.

[190]  I. Ishikawa,et al.  Prostaglandin E2 downregulates interleukin-12 production through EP4 receptors in human monocytes stimulated with lipopolysaccharide from Actinobacillus actinomycetemcomitans and interferon-gamma. , 2003, Oral microbiology and immunology.

[191]  T. Tsuchiya,et al.  Prostaglandin E2 Protects Gastric Mucosal Cells from Apoptosis via EP2 and EP4 Receptor Activation* , 2003, The Journal of Biological Chemistry.

[192]  J. Regan,et al.  Prostaglandin E2 Induced Functional Expression of Early Growth Response Factor-1 by EP4, but Not EP2, Prostanoid Receptors via the Phosphatidylinositol 3-Kinase and Extracellular Signal-regulated Kinases* , 2003, The Journal of Biological Chemistry.

[193]  R. Young,et al.  Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. , 2003, Bioorganic & medicinal chemistry letters.

[194]  C. Miyaura,et al.  Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis. , 2003, Biochemical and biophysical research communications.

[195]  R. Hotchkiss,et al.  The pathophysiology and treatment of sepsis. , 2003, The New England journal of medicine.

[196]  P. Libby,et al.  Prostaglandin E2 Suppresses Chemokine Production in Human Macrophages through the EP4 Receptor* , 2002, The Journal of Biological Chemistry.

[197]  D. Denis,et al.  The Immunomodulatory Actions of Prostaglandin E2 on Allergic Airway Responses in the Rat1 , 2002, The Journal of Immunology.

[198]  L. Audoly,et al.  The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. , 2002, The Journal of clinical investigation.

[199]  T. Luft,et al.  Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. , 2002, Blood.

[200]  Y. Kadowaki,et al.  Activation of prostaglandin E2-receptor EP2 and EP4 pathways induces growth inhibition in human gastric carcinoma cell lines. , 2002, The Journal of laboratory and clinical medicine.

[201]  I. Hirata,et al.  Expression of the EP4 Prostaglandin E2 Receptor Subtype with Rat Dextran Sodium Sulphate Colitis: Colitis Suppression by a Selective Agonist, ONO‐AE1‐329 , 2002, Scandinavian journal of immunology.

[202]  M. Toda,et al.  Design and synthesis of a selective EP4-receptor agonist. Part 4: practical synthesis and biological evaluation of a novel highly selective EP4-receptor agonist. , 2002, Bioorganic & medicinal chemistry.

[203]  K. Omote,et al.  Effects of a Novel Selective Agonist for Prostaglandin Receptor Subtype EP4 on Hyperalgesia and Inflammation in Monoarthritic Model , 2002, Anesthesiology.

[204]  J. Morrow,et al.  Selective cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in mice. , 2002, American journal of respiratory and critical care medicine.

[205]  K. Takeuchi,et al.  16,16-Dimethyl Prostaglandin E2 Inhibits Indomethacin-Induced Small Intestinal Lesions Through EP3 and EP4 Receptors , 2002, Digestive Diseases and Sciences.

[206]  S. Narumiya,et al.  The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. , 2002, The Journal of clinical investigation.

[207]  Ali Keshavarzian,et al.  Intestinal Permeation and Gastrointestinal Disease , 2002, Journal of clinical gastroenterology.

[208]  S. Narumiya,et al.  Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[209]  J. Regan,et al.  Phosphorylation of Glycogen Synthase Kinase-3 and Stimulation of T-cell Factor Signaling following Activation of EP2 and EP4 Prostanoid Receptors by Prostaglandin E2 * , 2002, The Journal of Biological Chemistry.

[210]  K. Takeuchi,et al.  Prostaglandin E prevents indomethacin-induced gastric and intestinal damage through different EP receptor subtypes , 2001, Journal of Physiology-Paris.

[211]  S. Narumiya,et al.  Increased Bleeding Tendency and Decreased Susceptibility to Thromboembolism in Mice Lacking the Prostaglandin E Receptor Subtype EP3 , 2001, Circulation.

[212]  B. Ashby,et al.  Agonist‐induced internalization and mitogen‐activated protein kinase activation of the human prostaglandin EP4 receptor , 2001, FEBS letters.

[213]  R. Millar,et al.  Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. , 2001, The Journal of clinical endocrinology and metabolism.

[214]  K. Takeuchi,et al.  Adaptive gastric cytoprotection is mediated by prostaglandin EP1 receptors: a study using rats and knockout mice. , 2001, The Journal of pharmacology and experimental therapeutics.

[215]  G. FitzGerald,et al.  Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. , 2001, The Journal of clinical investigation.

[216]  K. Takeuchi,et al.  Prostaglandin E Inhibits Indomethacin-Induced Gastric Lesions through EP-1 Receptors , 2001, Digestion.

[217]  H. Endo,et al.  Up‐regulation of prostaglandin E receptor EP2 and EP4 subtypes in rat synovial tissues with adjuvant arthritis , 2001, Clinical and experimental immunology.

[218]  B. Ashby,et al.  Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration. , 2000, Molecular pharmacology.

[219]  W. Arendshorst,et al.  EP(1) and EP(4) receptors mediate prostaglandin E(2) actions in the microcirculation of rat kidney. , 2000, American journal of physiology. Renal physiology.

[220]  B. Korelitz,et al.  Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study , 2000, American Journal of Gastroenterology.

[221]  H. Flad,et al.  Identification of Distinct Surface-Expressed and Intracellular CXC-Chemokine Receptor 2 Glycoforms in Neutrophils: N-Glycosylation Is Essential for Maintenance of Receptor Surface Expression1 , 2000, The Journal of Immunology.

[222]  R. Loutzenhiser,et al.  Biphasic actions of prostaglandin E(2) on the renal afferent arteriole : role of EP(3) and EP(4) receptors. , 2000, Circulation research.

[223]  R. Sartor,et al.  Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. , 2000, The Journal of clinical investigation.

[224]  K. Nakao,et al.  Crucial Involvement of the EP4 Subtype of Prostaglandin E Receptor in Osteoclast Formation by Proinflammatory Cytokines and Lipopolysaccharide , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[225]  K. Takeuchi,et al.  The roles of prostaglandin E receptor subtypes in the cytoprotective action of prostaglandin E2 in rat stomach , 2000, Alimentary pharmacology & therapeutics.

[226]  D. Zeldin,et al.  Allergic lung responses are increased in prostaglandin H synthase-deficient mice. , 1999, The Journal of clinical investigation.

[227]  A. Kurtz,et al.  Differential regulation of renal prostaglandin receptor mRNAs by dietary salt intake in the rat. , 1999, Kidney international.

[228]  M. Bastepe,et al.  Identification of a region of the C‐terminal domain involved in short‐term desensitization of the prostaglandin EP4 receptor , 1999, British journal of pharmacology.

[229]  B. Koller,et al.  Urinary concentrating function in mice lacking EP3 receptors for prostaglandin E2. , 1998, American journal of physiology. Renal physiology.

[230]  G. Ghosh,et al.  IκBα Functions through Direct Contacts with the Nuclear Localization Signals and the DNA Binding Sequences of NF-κB* , 1998, The Journal of Biological Chemistry.

[231]  Y. Nimura,et al.  Prostaglandin E2 protects against liver injury after Escherichia coli infection but hampers the resolution of the infection in mice. , 1998, Journal of immunology.

[232]  L. Audoly,et al.  A conserved threonine in the second extracellular loop of the human EP2 and EP4 receptors is required for ligand binding. , 1998, European journal of pharmacology.

[233]  R. Breyer,et al.  Prostaglandin E2 inhibits renal collecting duct Na+ absorption by activating the EP1 receptor. , 1998, The Journal of clinical investigation.

[234]  S. Narumiya,et al.  Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. , 1998, Biochemical and biophysical research communications.

[235]  G. C. Smith,et al.  The pharmacology of the ductus arteriosus. , 1998, Pharmacological reviews.

[236]  K. Takeuchi,et al.  Roles of prostaglandin E-receptor subtypes in gastric and duodenal bicarbonate secretion in rats. , 1997, Gastroenterology.

[237]  A. Ichikawa,et al.  Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. , 1996, Molecular pharmacology.

[238]  R. Phipps,et al.  Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[239]  S. Ortiz-Vega,et al.  Prostaglandin E2 both stimulates and inhibits adenyl cyclase on platelets: comparison of effects on cloned EP4 and EP3 prostaglandin receptor subtypes. , 1996, Prostaglandins.

[240]  S. Foord,et al.  The structure of the prostaglandin EP4 receptor gene and related pseudogenes. , 1996, Genomics.

[241]  S. Narumiya,et al.  Prostaglandin E receptor subtypes in mouse osteoblastic cell line. , 1996, Endocrinology.

[242]  H. Jacobson,et al.  Cloning and expression of the rabbit prostaglandin EP4 receptor. , 1996, The American journal of physiology.

[243]  S. Narumiya,et al.  Identification of prostaglandin E receptor ‘EP2’ cloned from mastocytoma cells as EP4 subtype , 1995, FEBS letters.

[244]  J. Regan,et al.  Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. , 1994, Molecular pharmacology.

[245]  P. O'Byrne,et al.  Effect of inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects. , 1994, American journal of respiratory and critical care medicine.

[246]  R. A. Coleman,et al.  A novel inhibitory prostanoid receptor in piglet saphenous vein. , 1994, Prostaglandins.

[247]  R. Roberti,et al.  Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. , 1993, Blood.

[248]  I. Pavord,et al.  Effect of inhaled prostaglandin E2 on allergen-induced asthma. , 1993, The American review of respiratory disease.

[249]  A. Macpherson,et al.  Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. , 1993, Gastroenterology.

[250]  Y. Sugimoto,et al.  Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. , 1993, The Journal of biological chemistry.

[251]  R. L. Jones,et al.  Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues , 1993, British journal of pharmacology.

[252]  S. Hayashi,et al.  Hepatocyte membrane stabilization by prostaglandins E1 and E2: favorable effects on rat liver injury. , 1992, Gastroenterology.

[253]  C. Spraggs,et al.  Prostanoid stimulation of anion secretion in guinea‐pig gastric and ileal muscosa is mediated by different receptors , 1990, British journal of pharmacology.

[254]  W. Jee,et al.  The role of prostaglandins in bone in vivo. , 1990, Prostaglandins, leukotrienes, and essential fatty acids.

[255]  H. Kaufmann,et al.  Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. , 1987, Annals of internal medicine.

[256]  L. Makowka,et al.  Protection of thermochemotherapeutic-induced lethal acute hepatic necrosis in the rat by 16,16-dimethyl prostaglandin E2. , 1983, The Journal of surgical research.

[257]  J. Stachura,et al.  Prostaglandin protection of carbon tetrachloride-induced liver cell necrosis in the rat. , 1981, Gastroenterology.

[258]  A. Pearlman,et al.  Pulsed Doppler echocardiographic determination of time of ductal closure in normal newborn infants. , 1981, The Journal of pediatrics.

[259]  H. Weiss,et al.  Prostaglandin E2 Potentiation of Platelet Aggregation Induced by LASS Endoperoxide: Absent in Storage Pool Disease, Normal after Aspirin Ingestion , 1976, British journal of haematology.

[260]  E. Salzman,et al.  CYCLIC 3′,5′‐ADENOSINE MONOPHOSPHATE IN HUMAN BLOOD PLATELETS IV. REGULATORY ROLE OF CYCLIC AMP IN PLATELET FUNCTION * , 1972, Annals of the New York Academy of Sciences.

[261]  P. Validire,et al.  The COX2/PGE2 Pathway Maintains Senescence of Chronic Obstructive Pulmonary Disease Fibroblasts. , 2013 .

[262]  T. Coşkun,et al.  Activation of prostaglandin E receptor 4 triggers secretion of gut hormone peptides GLP-1, GLP-2, and PYY. , 2013, Endocrinology.

[263]  S. Katiyar,et al.  Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E₂ and prostaglandin E₂ receptors. , 2011, Carcinogenesis.

[264]  P. Libby,et al.  Lack of EP4 receptors on bone marrow-derived cells enhances inflammation in atherosclerotic lesions. , 2011, Cardiovascular research.

[265]  S. Rennard,et al.  Prostaglandin E₂ inhibits human lung fibroblast chemotaxis through disparate actions on different E-prostanoid receptors. , 2011, American journal of respiratory cell and molecular biology.

[266]  M. Isobe,et al.  Roles of prostaglandin E2 in cardiovascular diseases. , 2011, International heart journal.

[267]  Krisztián Németh,et al.  Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production , 2009, Nature Medicine.

[268]  M. Isobe,et al.  Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury. , 2009, Cardiovascular research.

[269]  K. Saigenji,et al.  Gastric mucosal protection against ethanol by EP2 and EP4 signaling through the inhibition of leukotriene C4 production. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[270]  U. Moens,et al.  Multisite phosphorylation of the cAMP response element-binding protein (CREB) by a diversity of protein kinases. , 2007, Frontiers in bioscience : a journal and virtual library.

[271]  T. Nishiyama,et al.  Protective effect of prostaglandin EP4-receptor agonist on anti-glomerular basement membrane antibody-associated nephritis. , 2006, Journal of pharmacological sciences.

[272]  H. Kanetake,et al.  Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract. , 2005, The Journal of urology.

[273]  C. Vancheri,et al.  The lung as a privileged site for the beneficial actions of PGE2. , 2004, Trends in immunology.

[274]  S. Narumiya,et al.  Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. , 2002, Cancer research.

[275]  M. O’Banion,et al.  Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. , 1999, Critical reviews in neurobiology.

[276]  D. Dewitt,et al.  Prostaglandin endoperoxide H synthases-1 and -2. , 1996, Advances in immunology.

[277]  Y. Sugimoto,et al.  Prostanoid receptors and their biological actions. , 1993, Progress in lipid research.

[278]  K. Thierauch,et al.  Modulation of platelet activation by prostaglandin E2 mimics. , 1991, Advances in prostaglandin, thromboxane, and leukotriene research.

[279]  H. Kishimoto,et al.  Ultrastructural and histological studies on closure of the mouse ductus arteriosus. , 1990, Acta anatomica.

[280]  H. Shio,et al.  Prostaglandin E2: effects on aggregation, shape change and cyclic AMP of rat platelets. , 1972, Prostaglandins.